摘要
目的:探讨槲皮素通过RAS/RAF/MEK1信号通路对乳腺癌MCF-7细胞的作用机制。方法:将乳腺癌MCF-7细胞分为空白对照组、低剂量组、中剂量组、高剂量组、极高剂量组,采用CCK-8细胞活力检测法测定不同组别的MCF-7细胞24 h、48 h、72 h的细胞活性;采用流式细胞术检测不同组别MCF-7细胞的凋亡率;采用蛋白质印迹法检测不同组别MEK1、RAS、YAP蛋白的表达;采用免疫荧光染色观察雌激素受体、孕激素受体染色情况。结果:与空白对照组比较,低剂量组、中剂量组、高剂量组及极高剂量组的MCF-7细胞活力均出现下降,呈浓度依赖,不具有时间依赖性,差异有统计学意义(P<0.05);乳腺癌细胞MCF-7的晚期凋亡率明显增加,差异有统计学意义(P<0.05);低剂量组、中剂量组和极高剂量组MCF-7细胞的MEK1、RAS、YAP蛋白的表达出现不同程度下降,差异有统计学意义(P<0.05);低剂量组、中剂量组、高剂量组及极高剂量组的MCF-7细胞中雌激素受体、孕激素受体表达增加,差异有统计学意义(P<0.05)。结论:槲皮素具有针对乳腺癌MCF-7细胞的抗肿瘤作用,且具有浓度依赖性,其机制可能与对RAS/RAF/MEK1信号通路的抑制有关。
Objective:To investigate the mechanism of quercetin in inhibiting breast cancer Michigan cancer foundation-7(MCF-7) cells via the RAS/RAF/MEK1 signaling pathway.Methods:Breast cancer MCF-7 cells were classified into blank control and low-,medium-,high-,and extremely high-dose quercetin groups.The viability of MCF-7 cells in different groups cultured for 24,48,and 72 h were measured by the CCK-8 assay.The apoptosis rate of MCF-7 cells in different groups was determined by flow cytometry.The protein levels of MEK1,RAS,and YAP were determined by Western blotting.Immunofluorescence staining was employed to observe the expression of estrogen receptor and progesterone receptor.Results:Compared with the blank control group,quercetin decreased the viability of MCF-7 cells in a concentration-dependent and non-time-dependent manner(P<0.05).The apoptosis rate of MCF-7 cells increased in the late stage(P<0.05).Compared with blank control group,low-,medium-,and extremely high-dose quercetin down-regulated the expression of MEK1,RAS,and YAP in MCF-7 cells(P<0.05).All the doses of quercetin promoted the expression of estrogen receptor and progesterone receptor in MCF-7 cells(P<0.05).Conclusion:Quercetin exerts a dose-dependent antitumor effect on breast cancer MCF-7 cells by inhibiting the RAS/RAF/MEK1 signaling pathway.
作者
潘小娟
史晓光
汪唐顺
陈振宙
左禧萌
PAN Xiaojuan;SHI Xiaoguang;WANG Tangshun;CHEN Zhenzhou;ZUO Ximeng(Beijing University of Chinese Medicine,Beijing 100029,China;Dongzhimen Hospital,Beijing University of Chinese Medicine,Beijing 100700,China)
出处
《世界中医药》
CAS
2023年第20期2892-2898,共7页
World Chinese Medicine
基金
国家自然科学基金面上项目(81973849)
北京中医药大学基本科研业务费自主选题项目(2022-BUCMXJKY009)。
